Table 3.
Differences in stage shifts among expanded and non-expanded states, after stratifying for the type of cancer
| Category | Total sample | Expanded states | Non-expanded states | ||||||
| Type of cancer | Pre-Medicaid expansion (2011-2013) | Post-Medicaid expansion (2014-2015) | p value | Pre-Medicaid expansion (2011-2013) | Post-Medicaid expansion (2014-2015) | p value | Pre-Medicaid expansion (2011-2013) | Post-Medicaid expansion (2014-2015) | p value |
| Bone tumors | (n = 1196) | (n = 869) | (n = 955) | (n = 701) | (n = 241) | (n = 168) | |||
| < 0.001 | 0.006 | 0.01 | |||||||
| Stage I/II | 67% (800) | 76% (656) | 68% (646) | 75% (525) | 64% (154) | 78% (131) | |||
| Stage III/IV | 18% (218) | 14% (121) | 18% (170) | 14% (100) | 20% (48) | 13% (21) | |||
| 15% (178) | 11% (92) | 15% (139) | 11% (76) | 16% (39) | 10% (16) | ||||
| Unknown stage | |||||||||
| Soft-tissue sarcomas | (n = 3880) | (n = 2805) | (n = 3192) | (n = 2270) | (n = 688) | (n = 535) | |||
| 0.17 | 0.31 | 0.47 | |||||||
| Stage I/II | 55% (2137) | 57% (1608) | 55% (1769) | 57% (1303) | 54% (368) | 57% (305) | |||
| Stage III/IV | 38% (1461) | 36% (1010) | 37% (1185) | 36% (812) | 40% (276) | 37% (198) | |||
| 7% (282) | 7% (187) | 8% (238) | 7% (155) | 6% (44) | 6% (32) | ||||
| Unknown stage | |||||||||